Medtechs rake in the venture cash
In terms of private investments, 2020 was the year of the liquid biopsy.
Exact chases its dream with $1.7bn Thrive deal
Setting its sights on the screening setting, Exact aims to be a major liquid biopsy player.
With its liquid biopsy approval, Foundation Medicine takes on Guardant
The first pan-cancer approval might have gone to Guardant, but Roche’s subsidiary’s blood test appears to be able to find more markers.
AACR 2020 – Thrive steals a march
Thrive is in some ways ahead of the competition with the first-ever screening trial of a liquid biopsy, but the test’s sensitivity leaves something to be desired.
Medtech VC and the billion-dollar era
The first one-shot billion-dollar venture investment round in the medical technology sector has gone to Verily as computing bleeds into medicine.
Thrive emerges with cash, a cancer blood test, and a plan
A new player has entered the liquid biopsy game.